Home | Welcome to Contract Pharma   
Last Updated Wednesday, June 19 2013
Print

Financial Report: Enzon 3Q



Published November 3, 2009
Enzon 3Q09

3Q Revenues:
$44.6 million (-9%)

3Q Earnings:
$0.1 million (loss of $2.0 million in 3Q08)

Comments: Product sales in the quarter were down 1% to $28.6 million.
Contract manufacturing revenue was $2.3 million (-57%), primarily due to cancelled shipments and early discontinuation of processing for a CMO customer scheduled for termination in early 2010. Royalty revenue, for which Pegintron accounts for the majority, was $13.7 million (-6%).



blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On